Tevogen Bio Holdings Inc. (TVGN) is experiencing a surge in its stock price on Wednesday, fueled by an exciting announcement: its artificial intelligence arm, Tevogen AI, has joined forces with Microsoft Corporation (MSFT) for Startups. This strategic partnership promises to be a game-changer for Tevogen, granting the company unparalleled access to Microsoft’s robust ecosystem. This access is anticipated to significantly accelerate and streamline Tevogen’s algorithm development, propelling the company closer to its ambitious goal of reducing drug development costs, expediting drug discovery, and delivering transformative therapies to a wider patient population.
The company highlights the transformative potential of this collaboration, stating: “The partnership with Microsoft, the leading innovator in the AI space, is a substantial investment in Tevogen’s goal to provide affordable and accessible therapies. By leveraging Microsoft’s cutting-edge AI technology, Tevogen aims to push the boundaries of what AI can achieve in the biotech industry.”
Mittul Mehta, CIO and Head of Tevogen AI, emphasized the significant economic impact of Generative AI, citing The McKinsey Global Institute, which estimates that it could generate an annual economic value of $60 billion to $110 billion for pharmaceutical and medtech companies. Mehta confidently stated, “The metrics are astounding, and we are excited to contribute to that economic value.”
How to Invest in Tevogen Bio Holdings (TVGN)
The surge in TVGN’s stock price has likely piqued the interest of many investors. If you’re considering investing in Tevogen Bio Holdings, you can purchase shares through a brokerage account. Many platforms offer fractional shares, allowing you to own portions of stock without purchasing an entire share. As of this writing, TVGN is trading at $2.8, meaning $100 would buy you approximately 35.71 shares.
For investors who believe TVGN’s stock price might decline, there are options trading strategies available. These strategies involve either buying put options or selling call options at a strike price above the current share price. Both options can generate profits from a decrease in the share price.
Tevogen’s Price Action
The news of the Microsoft partnership has sent TVGN shares soaring. At the time of writing, TVGN is up a remarkable 60.3% at $2.58. This significant price jump reflects the market’s positive reaction to the potential of this strategic alliance.
This partnership between Tevogen and Microsoft holds immense promise for the future of drug discovery and development. It is a testament to the transformative power of AI in the biotech industry, and investors will be eagerly watching to see how this collaboration unfolds.
